HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico
Bibliographic record
Abstract
The development of potent interferon-free regimens of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection has moved at a remarkable pace. Highly effective, extremely well-tolerated regimens are now available for most patient populations. Remarkably, advances have moved as quickly for those with HIV–HCV co-infection as for those with HCV monoinfection, with recent studies showing similar results with most regimens in both populations. This has raised the question of whether HIV co-infection continues to represent a “special” population among HCV-infected individuals. There are, however, some data suggesting that HIV may still impair responses in particularly difficult-to-cure populations. For example, attempts to shorten therapy to eight weeks with sofosbuvir/NS5A combinations have been at least somewhat less successful in HIV-co-infected patients than in those with HCV monoinfection. It is clear that innate and possibly adaptive immune function are still necessary for viral clearance even with highly effective DAA-based regimens, and thus, it is possible that particularly as therapy is pushed to shorter and simpler combinations, HIV may again emerge as an issue necessitating special consideration. The rationale behind DAA combinations will be reviewed with a focus on relevance for HIV-HCV co-infection. A general discussion of remaining issues to be addressed including drug interactions and treatment access will also be included. 10.7448/IAS.19.2.21083 © 2016 Feld J; licensee International AIDS Society Published 28 April 2016
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.002 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.014 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".